{"id":"06824818-c2fa-4328-bc76-100d558c14e6","question":"What was the vaccine efficacy against symptomatic disease in the heterologous combination?","reference_answer":"92.0% (95%CI 80.4\u201396.7)","reference_context":"Document 6: Findings We included 44,031 participants (52.0% female, 48.0% male; median age 50 years, range 19\u201380 years; 7.0%\nblack, 24.0% mixed-race, 59.0% white) in a context of initial Beta VOC predominance, with this variant being partially\nreplaced by Delta near the trial\u2019s end. Vaccine ef\ufb01cacy in the heterologous combination was 92.0% (95%CI 80.4\u201396.7)\nagainst symptomatic disease. There were no severe COVID-19 cases in the vaccine group against 6 in the placebo\ngroup. Two doses of SOBERANA-02 was 69.7% (95%CI 56.5\u201378.9) and 74.9% (95%CI 33.7\u201390.5) ef\ufb01cacious\nagainst symptomatic and severe COVID-19, respectively. The occurrence of serious and severe adverse events (AE)\nwas very rare and equally distributed between placebo and vaccine groups. Solicited AEs were slightly more\nfrequent in the vaccine group but predominantly local and mostly mild and transient.","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":6,"topic":"Covid-19 Vaccine"}}
{"id":"c80fc415-e111-4e80-9f78-67800acde3ad","question":"What percentage of participants had serologic evidence of a previous SARS-CoV-2 infection at baseline?","reference_answer":"0.3% of participants","reference_context":"Document 38: 2021, 45.184 volunteers were screened and 44,031 were randomly assigned to So2 (14.679), So2P (14,677) or placebo (14,675) (Fig. 1). Participants\u2019 characteristics were balanced between the\nstudy arms (Table 1) and the gender and racial distri-\nbution were representative of the Cuban demographic\nstructure (see also S4-Table S3 for characteristics by age\nand risk of severe COVID-19). At baseline, serologic\nevidence of a previous SARS-CoV-2 infection was\ndetected\nin\n0.3%\nof\nparticipants. All\nparticipants\nArticles\nwww.thelancet.com Vol 18 February, 2023\n5","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":38,"topic":"Covid-19 Vaccine"}}
{"id":"55933395-bcf9-41a3-bf0e-f4e76aea0f8f","question":"What is the efficacy of the vaccine in preventing severe COVID-19, considering only the cases where hospitalization or death occurred?","reference_answer":"The vaccine efficacy for prevention of severe COVID-19 was 74.9% (95%CI: 33.7\u201390.5)","reference_context":"Document 49: for So2 and 2.2% for So2P) and headache (1.0% for placebo, 1.2% for So2 and 1.5% for So2P) (S9-Table S8). The occurrence of\nserious (<0.1%) and severe (0.1%) VAAE was equal be-\ntween groups (S8-Table S7, S10-Table S9). 3.9% of all\nthe AEs were grade 3 in the placebo group against 3.4%\nand 4.2% for groups So2 and So2P, respectively and\n7.9%, 6.7% and 6.7% were serious in these groups,\nrespectively. All-cause mortality was 24 (0.2%) amongst\nplacebo recipients against 9 and 11 (0.1%) in groups So2\nand So2P (P = 0.014). No death was vaccine related. Ef\ufb01cacy\nThe \ufb01nal analysis of the two-doses schedule included\n174 cases of symptomatic COVID-19: 136 in the placebo\ngroup (99.9 per 1000 person-years; 95%CI 83.8\u2013118.2)\nand 38 in the So2 group (30.5 per 1000 person-years;\n95%CI 21.6\u201341.9). This corresponds to 69.7% VE\n(95% CI 56.5\u201378.9%; P < 0.001) for the prevention of\nsymptomatic SARS-CoV-2 infection by the So2 schedule\n(Table 2, Fig. 3, S13-Fig. S2).\n\nDocument 50: P < 0.001) for the prevention of symptomatic SARS-CoV-2 infection by the So2 schedule (Table 2, Fig. 3, S13-Fig. S2). The vaccine ef\ufb01cacy to\nprevent COVID-19 was congruous across subgroups\nstrati\ufb01ed by demographic and baseline characteristics\n(S14-Fig. S3). The VE for prevention of severe COVID-19 (23 cases\nin placebo vs 5 in So2) was 74.9% (95%CI: 33.7\u201390.5)\n(S12-Table S10). There were 3 and 2 deaths from\nCOVID-19 disease, respectively; the small number of\nevents precludes a point estimate of VE. For the \ufb01nal analysis of the three-dose heterologous\nSo2P schedule 41 cases of COVID-19 were included: 35\nin the placebo group (91.4 per 1000 person-years; 95%\nCI 63.4\u2013126.6) and 6 in the So2P group, (6.6 per 1000\nperson-years; 95%CI 2.4\u201314.5). This means 92.0% VE\n(95%CI 80.4\u201396.7%; P < 0.001) for prevention of\nsymptomatic\nSARS-CoV-2\ninfection\nby\nthe\n3-dose\nschedule (Table 2, Fig. 3, S15-Fig. S4).","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":49,"topic":"Others"}}
{"id":"97811721-15bf-4c3c-b972-7819e30dd982","question":"What was the efficacy of the vaccine against symptomatic COVID-19 disease in participants receiving a combination of two different vaccines, as measured by the percentage of participants who developed symptomatic disease?","reference_answer":"92.0% (95%CI 80.4\u201396.7)","reference_context":"Document 6: Findings We included 44,031 participants (52.0% female, 48.0% male; median age 50 years, range 19\u201380 years; 7.0%\nblack, 24.0% mixed-race, 59.0% white) in a context of initial Beta VOC predominance, with this variant being partially\nreplaced by Delta near the trial\u2019s end. Vaccine ef\ufb01cacy in the heterologous combination was 92.0% (95%CI 80.4\u201396.7)\nagainst symptomatic disease. There were no severe COVID-19 cases in the vaccine group against 6 in the placebo\ngroup. Two doses of SOBERANA-02 was 69.7% (95%CI 56.5\u201378.9) and 74.9% (95%CI 33.7\u201390.5) ef\ufb01cacious\nagainst symptomatic and severe COVID-19, respectively. The occurrence of serious and severe adverse events (AE)\nwas very rare and equally distributed between placebo and vaccine groups. Solicited AEs were slightly more\nfrequent in the vaccine group but predominantly local and mostly mild and transient.","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":6,"topic":"Covid-19 Vaccine"}}
{"id":"b6c756a8-8fed-418e-9838-d14140342003","question":"What is the reason for excluding individuals who have received a COVID-19 vaccine within the last 30 days in an open-label phase 1 clinical trial?","reference_answer":"Current or planned receipt of immunomodulatory drugs","reference_context":"Document 23: to use reliable anticonception if female and in fertile age, and that provided written informed consent for participation were included. Exclusion criteria were previous receipt\nof a COVID-19 vaccine, acute febrile illness or infectious\ndisease, pregnancy, puerperium or breastfeeding, any\nuncontrolled non-communicable disease, history of a\nsevere allergic reaction to any component of the vac-\ncines, current or planned (within 30 days) receipt of\nimmunomodulatory drugs, history of COVID-19 infec-\ntion, decreased mental ability to take decisions, tattoos\nin the deltoid region of both arms, and administration of\ntetanus anatoxin-containing vaccines within the last 3\nmonths. At inclusion, a blood sample for asserting rapid\nserologic evidence of SARSCoV-2 prior asymptomatic\ninfection (Realy Tech IgG\/IgM, China) was collected in\norder to subsequently permit safety and ef\ufb01cacy ana-\nlyses strati\ufb01ed by prior exposure.","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":23,"distracting_context":"open-label phase 1 clinical trial. Lancet Reg Health Am. 2021;4:100079. https:\/\/doi.org\/10.1016\/j.lana.2021.100079. 10 Bates TA, Mcbride SK, Leier HC, et al. Vaccination before or after\nSARS-CoV-2 infection leads to robust humoral response and anti-\nbodies that effectively neutralize variants. Sci Immunol. 2022;7:\neabn8014. https:\/\/doi.org\/10.1126\/sciimmunol.abn801. 11\nToledo-Romani ME, Garc\u00eda-Carmenate M, Verdecia-S\u00e1nchez L,\net al. Safety and immunogenicity of anti-SARS-CoV-2 heterologous\nscheme with SOBERANA 02 and SOBERANA Plus vaccines: phase\nIIb clinical trial in adults. Med. 2022;3:760\u2013773. https:\/\/doi.org\/10. 1016\/j.medj.2022.08.0011. 12\nGuzm\u00e1n MG, Perez L, Tejero Y, et al. Emergence and evolution of\nSARS-CoV-2 genetic variants during the Cuban epidemic. J Clin\nVirol. 2022;2:100104. https:\/\/doi.org\/10.1016\/j.jcvp.2022.100104. 13\nFood and Drug Administration. E6(R2) good clinical practice: in-\ntegrated addendum to ICH E6(R1).","topic":"Covid-19 Vaccine"}}
{"id":"5598ee8a-795d-40cf-8323-71dd708180ad","question":"What specific time frame is used to calculate vaccine efficacy, and how is it defined in the context of the vaccine administration schedule?","reference_answer":"The VE for So2P was estimated considering the So2P and control arm cases occurring in the same calendar period (14 days after dose 3 in So2P and 42 days after the 2nd dose in placebo).","reference_context":"Document 35: 106 symptomatic cases meeting the primary outcome de\ufb01nition. We used person-time of exposure in the summary statistics and group comparisons. Vaccine ef\ufb01cacy was\ncalculated in the per-protocol population (PPP) as\npercentage reduction in the HR: VE = 100 \u00d7 (1 \u2013 HR) %,\nin the vaccine groups as compared to the placebo group,\nwith HR estimated from a strati\ufb01ed Cox proportional\nhazards model taking into account the de\ufb01ned risk\nstrata. To take the evolution of the epidemiological sit-\nuation over time into account, the VE for So2P was\nestimated considering the So2P and control arm cases\noccurring in the same calendar period (14 days after\ndose 3 in So2P and 42 days after the 2nd dose in\nplacebo). Safety was assessed in all participants in the safety\npopulation (those who received at least one injection).","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":35,"distracting_context":"informed consent forms. In the event of a medical problem requiring unmasking, approval by the principal investigator was planned for. All principles of the Helsinki Declaration and the In-\nternational Council for Harmonization guidelines were\nadhered to.13 Full details on procedures are provided in\nthe protocol. The National Clinical Trials Coordinating Centre\n(CENCEC) monitored the trial for protocol adherence\nand observance of Good Clinical Practice and oversaw\ndata accuracy. An Independent Safety Data Monitoring\nBoard (ISDMB) continuously supervised safety and\nconducted interim analysis. The ISDMB had access to\nthe case \ufb01les, con\ufb01rmed severe cases of COVID-19\nillness, and assessed whether any deaths were SARS\nCoV-2-related. Participants, randomisation and blinding\nIn 8 municipalities of west Havana we set up, in existing\nhealth infrastructure, 48 vaccination and clinical sites.","topic":"Vaccine Safety Study"}}
{"id":"d7ca1ba1-3211-45a0-be80-5efad31ee188","question":"As a researcher from a prestigious institution, I am writing a scientific paper about a medical trial and I want to express my gratitude to the volunteers and clinical experts who contributed to the study. I also want to assure the readers that I have no personal conflicts of interest. Where should I send my proposal for full data sharing?","reference_answer":"Proposals for full data sharing should be sent to mariaeugenia@ipk.sld.cu, vicente.verez@finlay.edu.cu or ci\ufb01nlay@finlay.edu.cu.","reference_context":"Document 69: be made available after publica- tion. Proposals for full data sharing should be sent to: mariaeugenia@ ipk.sld.cu, vicente.verez@\ufb01nlay.edu.cu or ci\ufb01nlay@\ufb01nlay.edu.cu. These proposals will be reviewed and must be approved by the sponsor\nand the senior investigators. Lastly, a data access agreement must be\nsigned. Declaration of interests\nVVB, YVB, DGR, YCR, SFC are authors of two patent applications. The\nother authors declare no competing interests. No author received an\nhonorarium for contributing to this paper. Acknowledgments\nWe especially thank all the volunteers who participated in the trial and\nthe members of the SOBERANA-Phase 3 clinical trial team (listed in the\nSupplementary Information) for their dedication and contributions to\nthe trial. We further thank the IDSMB members: N. A. Jimenez Perez (Chair\nand Clinical Expert) and C. M. Fonseca G\u00f3mez (Clinical Expert) from\nthe Pedro Kour\u00ed Tropical Medicine Institute, G. Mar\u00eda Su\u00e1rez Formigo\n(Immunological Expert) and P.","conversation_history":[],"metadata":{"question_type":"situational","seed_document_id":69,"situational_context":"A researcher from a prestigious institution is writing a scientific paper about a medical trial, specifically thanking volunteers and clinical experts for their contributions to the study, while declaring no personal conflicts of interest.","topic":"Others"}}
{"id":"4f917d96-26a7-4d32-b2e8-267ddc21097e","question":"As a researcher in a developing country, what is a key advantage of the SOBER-ANA vaccines that would make them a more practical choice for our region, where access to cold storage is limited?","reference_answer":"They are easier to distribute and use than those vaccines that must be stored at much lower temperatures and require powerful freezers.","reference_context":"Document 66: easier to distribute and use than those vaccines that must be stored at much lower temperatures and require powerful freezers. This represents a key advan-\ntage in less-wealthy countries. Furthermore, they rely on\nan established and widely used vaccine technology, and\ntheir production can be cost-effectively implemented\nand scaled up in biotechnology facilities in the global\nsouth that are manufacturing other protein subunit\nproducts. Overall, our results indicate that the SOBER-\nANA vaccines are ef\ufb01cacious in a context of Beta and\nDelta VOC circulation, have a favourable safety pro\ufb01le,\nand constitute an attractive, feasible option for use in\nCOVID-19 vaccination. Contributors\nMETR, CVS, YVB, DGR and VVB conceptualised the study. METR,\nMGC, ECG, LET, RDG, SGB, SPC, SHF, KIC, OFG, DMP, IRR, MRO,\nNHM were clinical investigators. MRG, BPM, IMH supervised and\nmonitored the trial. CVS, WBR and PVdS performed the statistical\nanalysis.","conversation_history":[],"metadata":{"question_type":"situational","seed_document_id":66,"situational_context":"A researcher from a developing country is advocating for the use of a new vaccine that offers an advantage over traditional vaccines requiring ultra-low temperatures.","topic":"Covid-19 Vaccine"}}
{"id":"cc9d2e53-673a-4518-89e2-c40a0cdde502","question":"Who supervised and monitored the trial, and who wrote the manuscript?","reference_answer":"The trial was supervised and monitored by MRG, BPM, IMH, and the manuscript was written by METR, CVS, WBR, DGR, YVB, VVB, and PVdS.","reference_context":"Document 67: NHM were clinical investigators. MRG, BPM, IMH supervised and monitored the trial. CVS, WBR and PVdS performed the statistical analysis. RGMR, OST, PVV, JPBC and ELM were involved in data\nacquisition and data curation. SFC, YCR, YVB, MMP were responsible\nfor vaccine development, manufacturing and project administration. DD, MMG and AB contributed to trial design. METR, CVS, WBR, DGR,\nYVB, VVB and PVdS wrote the manuscript. All authors critically\nreviewed\nthe\nmanuscript\nfor\nimportant\nintellectual\ncontent\nand\napproved the \ufb01nal version. METR, MGC and CVS directly accessed and\nveri\ufb01ed the underlying data. VVB and METR were responsible for the\ndecision to submit the paper. Articles\nwww.thelancet.com Vol 18 February, 2023\n11","conversation_history":[],"metadata":{"question_type":"double","original_questions":[{"question":"Who supervised and monitored the trial?","answer":"MRG, BPM, IMH supervised and monitored the trial."},{"question":"Who wrote the manuscript?","answer":"METR, CVS, WBR, DGR, YVB, VVB and PVdS wrote the manuscript."}],"seed_document_id":67,"topic":"Others"}}
{"id":"b2c38a1a-1d26-4bad-9cb9-0f537403f100","question":"What is the purpose of a dictionary?","reference_answer":"The Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 is used for assessing the causality of adverse events following immunisation.","reference_context":"Document 75: participants: an open-label phase 2a and double-blind, randomised, placebo-controlled, phase 2b, seamless, clinical trial. Lancet Respir Med. 2022;10:785\u2013795. https:\/\/doi.org\/10.1016\/ S2213-2600(22)00100-X. 16\nP\u00e9rez-Rodr\u00edguez S, Rodr\u00edguez-Gonz\u00e1lez MC, Ochoa-Azze R, et al. A randomised, double-blind phase I clinical trial of two recombi-\nnant dimeric RBD COVID-19 vaccine candidates: safety, reac-\ntogenicity\nand\nimmunogenicity. Vaccine. 2022;40:2068\u20132075. https:\/\/doi.org\/10.1016\/j.vaccine.2022.02.029. 17\nUS Department of Health and Human Services. Common Termi-\nnology Criteria for Adverse Events (CTCAE). Version 5.0. Washington:\nHHS; 2017. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_\napplications\/ctc.htm#ctc_50. Accessed February 2021. 18\nWorld Health Organization. Causality Assessment of an Adverse Event\nFollowing ImmunisationImmunisation (AEFI). 2nd ed. Geneva:\nWHO;\n2018. https:\/\/appswho.int\/iris\/bitstream\/handle\/10665\/\n259959\/9789241513654-eng.pdf.","conversation_history":[{"role":"user","content":"The Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 is used to document adverse events."},{"role":"assistant","content":"How can I help you with that?"}],"metadata":{"question_type":"conversational","seed_document_id":75,"topic":"Covid-19 Vaccine"}}
{"id":"ff77e35b-7ab0-496c-b92a-7f01e3d895ca","question":"How long do solicited systemic AEs last after the third dose?","reference_answer":"2 days after the third dose (25\u201375th percentile: 0.8\u20137.5)","reference_context":"Document 48: after the third dose (Fig. 2, S6-Table S4, S7-Table S5, S8-\nTable S6). Their severity in the vaccine groups changed\nslightly from 6.5% after the \ufb01rst dose to 8.8% after the\nsecond dose for grade 2 events, and from 0.6% to 0.4%\nfor grade 3 ones. Solicited systemic AEs in the vaccine\ngroups lasted a median of 1 day after the \ufb01rst (25\u201375th\npercentile: 0\u20132) and second doses (25\u201375th percentile:\n0\u20133), and 2 days after the third dose (25\u201375th percentile:\n0.8\u20137.5). The frequency of solicited AE was very low in\nsubject with serologic evidence of a past SARSCoV-2\ninfection at intake: 0.1% of local AE after any injection\nand <0.1% of systemic events. Unsolicited AE frequency reported during the 28\ndays following each injection was similar in all groups. The more frequent events (\u22651%) were a high blood\npressure measurement, mainly in subjects with known\nhypertension (1.8% for placebo, 2.1% for So2 and 2.2%\nfor So2P) and headache (1.0% for placebo, 1.2% for So2\nand 1.5% for So2P) (S9-Table S8).","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":48,"topic":"Vaccine Safety Study"}}
{"id":"1d0c2e6e-2424-421e-ad4a-1cad9c9b65f8","question":"What percentage of local adverse events were grade 3?","reference_answer":"less than 0.2%","reference_context":"Document 41: ef\ufb01cacy anal- ysis included 42509 subjects: 14354 in the So2, 13871 in the So2P, and 14284 in the placebo group. Follow-up\nfrom 14 days after the second dose in the two doses\nanalysis totalled 70,959 and 64,926 persons-weeks in the\nplacebo and So2 arm, respectively, while in the three\ndoses analysis the corresponding follow-up time was\n20,047 persons-weeks in the placebo and 47,088 per-\nsons-weeks in the So2P group. Safety\nLocal\nsolicited\nVaccine-Associated\nAdverse\nEvents\n(VAAEs) occurred somewhat more frequently in the\nvaccine group than in the placebo group after the \ufb01rst\ndose (7.7%, vs. 2.6%, 95%CI for difference: 4.7\u20135.5%)\nand the second dose (1.9%, vs. 0.4%, 95%CI for differ-\nence: 1.3\u20131.7%) (Fig. 2, S6-Table S4, S7-Table S5). After\nthe third dose, the frequency of subjects with local AEs\ndropped to 0.3% (S7-Table S6). In the vaccine groups\n97.5% of local adverse events were grade 1 and less than\n0.2% grade 3.","conversation_history":[],"metadata":{"question_type":"simple","seed_document_id":41,"topic":"Vaccine Safety Study"}}
{"id":"96cb5ccd-38f2-4f7d-840d-a7ba023e2ec3","question":"What percentage of participants withdrew their consent after receiving both doses of the treatment?","reference_answer":"0.38%","reference_context":"Document 40: received the \ufb01rst dose of the treatment they were allo-\ncated to. After receiving the \ufb01rst dose, 168 (0,38%) partici-\npants withdrew their consent and did not receive the\nsecond dose and after that dose, 7 (0,05%) participants\nfrom the So2P group withdrew their consent. 412\n(0.94%) and 123 (0.84%) participants diagnosed with\nsymptomatic PCR positive SARS-CoV-2 infection were\nexcluded before receiving the second and the third dose,\nrespectively. Protocol deviations - 364 (0.83%) in total-\nwere due to intercurrent vaccination with another vac-\ncine (53.8%), errors in the administration of the candi-\ndate product (11.2%), incorrect inclusion (2.7%) and\nother reasons (32.1%). The PPP primary ef\ufb01cacy anal-\nysis included 42509 subjects: 14354 in the So2, 13871 in\nthe So2P, and 14284 in the placebo group.","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":40,"topic":"Others"}}
{"id":"f2419373-86d0-48ee-a318-ebe9fb9da76e","question":"What type of vaccine is being discussed in the context of COVID-19 and its potential applications in preventing other infectious diseases?","reference_answer":"The vaccine being discussed is a COVID-19 vaccine, specifically a RBD-tetanus toxoid conjugate vaccine","reference_context":"Document 71: clinical ef\ufb01cacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021;11:22777. https:\/\/doi.org\/10.1038\/ s41598-021-02321-z. 3 WHO. Vaccine equity. https:\/\/www.who.int\/campaigns\/vaccine-\nequity. Accessed February 22, 2021. 4\nValdes-Balbin Y, Santana-Medero D, Quintero L, et al. SARS-CoV-2\nRBD-tetanus toxoid conjugate vaccine induces a strong neutralising\nimmunity in preclinical studies. ACS Chem Biol. 2021;16:1223\u2013\n1233. https:\/\/doi.org\/10.1101\/2021.02.08.430146. 5\nSchneerson R, Robbins JB, Barrera O, et al. Haemophilus in\ufb02u-\nenzae type B polysaccharide-protein conjugates: model for a new\ngeneration of capsular polysaccharide vaccines. Prog Clin Biol Res. 1980;47:77\u201394. 6\nGoldblatt D. The indirect effect of pneumococcal conjugate vaccine. Lancet Glob Health. 2017;5:e6\u2013e7. https:\/\/doi.org\/10.1016\/S2214-\n109X(16)30338-2. 7\nGasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin. 2011;7:170\u2013182. https:\/\/doi.org\/10.4161\/hv.7.2.13717.","conversation_history":[],"metadata":{"question_type":"complex","seed_document_id":71,"topic":"Covid-19 Vaccine Efficacy"}}
{"id":"ae6aec67-eade-4250-acc2-4f3bd3d03cc1","question":"What is the name of the vaccine being studied in a phase 2b clinical trial, specifically at the Finlay Vaccine Institute in Havana, Cuba?","reference_answer":"FINLAY-FR-1A vaccine","reference_context":"Document 74: J Clin Virol. 2022;2:100104. https:\/\/doi.org\/10.1016\/j.jcvp.2022.100104. 13 Food and Drug Administration. E6(R2) good clinical practice: in- tegrated addendum to ICH E6(R1). Guidance for Industry https:\/\/\nwww.fda.gov\/regulatory-information\/search-fda-guidance-documents\/\ne6r2-good-clinical-practice-integrated-addendum-ich-e6r1; 2018. Accessed\nFebruary 2021. 14\nP\u00e9rez-Caballero MD, Le\u00f3n-\u00c1lvarez JL, Due\u00f1as-Herrera A, et al. Cuban guide for hypertension diagnosis, evaluation and treatment. Rev Cubana Med. 2017;56:242\u2013321. Available: http:\/\/scielo.sld.cu\/\nscielo.php?script=sci_arttext&pid=S0034-75232017000400001&lng=es. 15\nOchoa-Azze R, Chang-Monteagudo A, Climent-Ruiz Y, et al. Safety\nand immunogenicity of the FINLAY-FR-1A vaccine in COVID-19\nconvalescent participants: an open-label phase 2a and double-blind,\nrandomised, placebo-controlled, phase 2b, seamless, clinical trial. Lancet\nRespir\nMed. 2022;10:785\u2013795. https:\/\/doi.org\/10.1016\/\nS2213-2600(22)00100-X.","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":74,"distracting_context":"Av \u201cNovia del Mediod\u00eda\u201d, Kv 6 1\/2, La Lisa, Habana, 11400, Cuba\nbHavana Hygiene and Epidemiology Center, Havana, Cuba\ncCybernetics, Mathematics and Physics Institute. 15th St #55, Vedado, Plaza de la Revoluci\u00f3n, Havana, 10400, Cuba\ndFinlay Vaccine Institute. 21st Ave. N\u25e619810 between 198 and 200 St, Atabey, Playa, Havana, Cuba\neNational Coordinating Center for Clinical Trials. 5th Ave and 62, Miramar, Playa, Havana, Cuba\nf\u201cJos\u00e9 Antonio Echevarr\u00eda\u201d Technological University, Havana, Cuba\ngUCT Geocuba Research and Consulting, Havana, Cuba\nhMunicipal Health Department, Centro Habana, Havana, Cuba\niMunicipal Health Department, La Lisa, Havana, Cuba\njMunicipal Health Department, 10 de Octubre, Havana, Cuba\nkMunicipal Health Department, Habana Vieja, Havana, Cuba\nlMunicipal Health Department, Cerro, Havana, Cuba\nmMunicipal Health Department, Marianao, Havana, Cuba\nnMunicipal Health Department, Playa, Havana, Cuba\noMunicipal Health Department, Plaza Havana, Cuba\npPasteur Institute of Iran. No.","topic":"Covid-19 Vaccine"}}
{"id":"a1b3cd5a-0886-430c-93ad-bb9e9f59a744","question":"What percentage of SARS-CoV-2 infections among the study subjects were prevented by the 3-dose vaccination schedule, considering the unique code assigned to each subject ensured confidentiality and data accuracy?","reference_answer":"80.4\u201396.7%","reference_context":"Document 51: 80.4\u201396.7%; P < 0.001) for prevention of symptomatic SARS-CoV-2 infection by the 3-dose schedule (Table 2, Fig. 3, S15-Fig. S4). Subgroup\u2019s\nanalysis yields remarkably consistent VE estimates, but\nlacks precision for much of the strata (S16-Fig. S5). Severe COVID-19 occurred in 6 and 0 participants in the\nplacebo and So2P group, respectively (S12-Table S10). There were no deaths from COVID-19 disease. Including in the analysis subjects that were PCR\nnegative but had a IgG\/IgM positive test at inclusion,\nindicating past SARSCoV-2 infection, did not affect any\nof the VE estimates reported in all the above PPP\nanalysis. Discussion\nThe SOBERANA vaccines demonstrated to be ef\ufb01ca-\ncious\nin\npreventing\nPCR-con\ufb01rmed\nsymptomatic\nSARS-CoV-2\ninfections\namong\nadults\naged\n19\u201380\nyears. Ef\ufb01cacy\nafter\ntwo\ndoses\nSOBERANA-02\nadministration, 69.7%, was well over the WHO-set\n50% threshold.19 After completion of the heterolo-\ngous schedule with SOBERANA-Plus, VE attained an\nexcellent 92.0%.","conversation_history":[],"metadata":{"question_type":"distracting element","seed_document_id":51,"distracting_context":"store study subjects\u2019 general demographic and clinical\ninformation, speci\ufb01c data on the possible occurrence\nand subsequent course of a symptomatic COVID-19\ndisease episode, and information on adverse events. We made use of the national online registry ANDAR-\nIEGO.HIGIA\n(GEOCUBA,\nCuba,\nhttp:\/\/higia. andariego.cu) platform to store the participants\u2019 vacci-\nnation records and follow up their PCR results. The\nplatform registers COVID-19 doses administered in all\nvaccination centres in Cuba, and results of PCR tests\nperformed in all laboratories of the health system. To digitalise the primary information, we employed\ndata operators who were trained in the use of the soft-\nware packages. Both platforms provide an exhaustive\nchange control record, ensuring security and integrity,\nand allow data export. A unique code assigned to each\nsubject at enrolment guaranteed con\ufb01dentiality and\npermitted linking information from both sources.","topic":"Covid-19 Vaccine"}}
{"id":"2071d27c-f320-40ea-88b3-f3a5afd2f48b","question":"As a researcher who has worked on high-stakes studies like COVID-19 hospital documentation, I'm reviewing the efficacy of a novel vaccine and need to confirm which laboratory is responsible for confirming COVID-19 through RT-PCR.","reference_answer":"The SARS CoV-2 national reference laboratory at the \u201cPedro Kour\u00ed\u201d Tropical Medical Institute, Havana, Cuba.","reference_context":"Document 28: COVID-19 hospital doctors and reviewed by speci\ufb01cally trained medical research team members. The study\u2019s Principal Investigator resolved any discrep- ancy. COVID-19 symptomatic disease was considered if\nparticipants had at least one major symptom or sign\n(dyspnoea, oxygen saturation \u226492%, persistent thoracic\npain, neurological disorders, clinical or radiographic\nevidence of pneumonia) or two minor symptoms (fever,\nchills, myalgia, headache, sore throat, running nose,\ndiarrhoea\/vomiting, myalgia, malaise, cough, dysgeu-\nsia\/anosmia). In that case RT-PCR (QIAGEN, Germany)\ncon\ufb01rmation was performed by the SARS CoV-2\nnational reference laboratory at the \u201cPedro Kour\u00ed\u201d\nTropical Medical Institute, Havana, Cuba.","conversation_history":[],"metadata":{"question_type":"situational","seed_document_id":28,"situational_context":"A researcher, reviewing the efficacy of a novel vaccine, scrutinizes the data with a keen eye for precision, having worked on several high-stakes studies, including the COVID-19 hospital documentation.","topic":"Covid-19 Vaccine"}}
{"id":"c004a770-76af-4b47-91ca-b034af7c6e48","question":"As a researcher studying the effects of multi-task learning on patient outcomes, what medical conditions would make a patient ineligible for a program, assuming the patient already has a serious medical condition and is considering a recent paper on this topic?","reference_answer":"kidney disease, ischemic heart disease, diabetes mellitus, chronic obstructive pulmonary disease, asthma (grade 2\/3), cancer, HIV or primary\/secondary immunodeficiency.","reference_context":"Document 45: kidney disease, ischemic heart disease, diabetes mellitus, chronic obstructive pulmonary disease, asthma (grade 2\/3), cancer, HIV or primary\/secondary\nimmunode\ufb01ciency.","conversation_history":[],"metadata":{"question_type":"situational","seed_document_id":45,"situational_context":"A doctor is researching potential comorbidities for a patient with a serious medical condition, considering a recent paper on multi-task learning.","topic":"Others"}}
{"id":"0a0017c8-fec2-4aed-a5cf-e79bfdefbf08","question":"What measures do you take to ensure data confidentiality and monitor the quality of your clinical trials?","reference_answer":"A unique code assigned to each subject at enrolment guarantees confidentiality, while site visits verify adherence to the study protocol, good clinical practise, and standard operating procedures.","reference_context":"Document 32: data export. A unique code assigned to each subject at enrolment guaranteed con\ufb01dentiality and permitted linking information from both sources. The\nsponsor\u2019s staff ensured data export and cleansing for the\nsubsequent carrying out the interim and \ufb01nal analyses. All data management activities were governed by\nstandardised working procedures. We developed a monitoring and audit plan for\nquality control. During site visits, the proper conduct of\nthe trial was veri\ufb01ed by assessing adherence to the study\nprotocol, good clinical practise, and standard operating\nprocedures. We systematically checked the completion\nof all records and the quality of digitalization. The visits\nalso made it possible to detect and correct any differ-\nential assessments of clinical events between centres.","conversation_history":[],"metadata":{"question_type":"double","original_questions":[{"question":"What measures do you take to ensure data confidentiality?","answer":"A unique code assigned to each subject at enrolment guaranteed con\ufb01dentiality"},{"question":"How do you monitor the quality of your clinical trials?","answer":"During site visits, the proper conduct of the trial was veri\ufb01ed by assessing adherence to the study protocol, good clinical practise, and standard operating procedures."}],"seed_document_id":32,"topic":"Others"}}
{"id":"f4b11975-da4a-4f2b-aa1e-dc301b47009c","question":"What is the efficacy for?","reference_answer":"92.0%","reference_context":"Document 52: well over the WHO-set 50% threshold.19 After completion of the heterolo- gous schedule with SOBERANA-Plus, VE attained an excellent 92.0%. Ef\ufb01cacy to prevent severe COVID-19\nwas 74.9% for the two doses regimen; no severe\ncase presented under the heterologous scheme. The\noccurrence of serious and severe AEs was very rare\nCOVID-19 disease\nTwo-dose Vaccine Ef\ufb01cacy\nPlacebo\nSo2\nn of events, PPP\n136\n38\nPerson- weeks follow-up\n70,959\n64,926\nIncidence rate per 1000 Person-Years (95% CI)\n99.9 (83.8; 118.2)\n30.5 (21.6; 41.9)\nVaccine Ef\ufb01cacy (95%CI)\n69.7 (56.5; 78.9)\nHeterologous three-dose Vaccine Ef\ufb01cacy\nPlacebo\nSo2P\nn of events, PPP\n35\n6\nPerson- weeks follow-up\n20,047\n47,088\nIncidence rate per 1000 Person-Years (95% CI)\n91.4 (63.4; 126.6)\n6.6 (2.4; 14.5)\nVaccine Ef\ufb01cacy (95% CI)\n92.0 (80.4; 96.7)\nVaccine ef\ufb01cacy was de\ufb01ned as (1 - minus the hazard ratio)*100%, (Vaccine vs. placebo), and the 95% con\ufb01dence interval was estimated with the use of a strati\ufb01ed Cox\nproportional hazards model.","conversation_history":[{"role":"user","content":"The vaccine efficacy is for the heterologous three-dose regimen."},{"role":"assistant","content":"How can I help you with that?"}],"metadata":{"question_type":"conversational","seed_document_id":52,"topic":"Covid-19 Vaccine"}}
